drugset
drugset / Trial / NCT01064713

Phase II Study of Tesetaxel in Metastatic Melanoma

NCT01064713 ↗

Phase 2 Completed 17 enrolled M.D. Anderson Cancer Center Genta Incorporated · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.

Timeline

Start
2010-02
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tesetaxel Small molecule 40 mg Oral
Subject Tesetaxel Small molecule 50 mg Oral

Indications

cancer melanoma